Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice.
PMID: 34327247
2021
Open forum infectious diseases
Table: V75I
HIV-1 molecular transmission network among sexually transmitted populations in Liaoning Province, China.
Result: Among them, 9 cases were protease inhibitor-related resistance, and the main resistance sites were L33F, V82A, Q58E, M46L, M46I; There were 4 cases of nucleoside reverse transcriptase inhibitor resistance, the main mutation sites were V75VI, K219Q, T215A, K65R; There were 5 cases of non-nucleoside reverse transcriptase inhibitor resistance, the main mutation sites were V179E, A98G, V106I, Y181C, G190S
High HIV-1 Virological Failure and Drug Resistance among Adult Patients Receiving First-Line ART for At least 12 Months at a Decentralized Urban HIV Clinic Setting in Senegal before the Test-and-Treat.
Method: As of fact, the mutation V75VI often occurs along with the multi-resistance Q151M, but when alone its clinical significance is uncertain so was not considered in the definition of drug resistance (http://hivdb.stanford.edu).
High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.
PMID: 32105319
2020
The Journal of antimicrobial chemotherapy
Table: V75I
Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.
Introduction: In vitro selection experiments indicated that substitutions in the 74 position combined with major mutations (G140A/C/S, Q148 H/K/R) and other accessory mutations (V75I, T97A) can significantly reduce susceptibility to INSTI, whereas this mutation alone has minimal impact on INSTI susceptibility or HIV-1 replication capacity.
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya.
PMID: 33654530
2020
The Pan African medical journal
Table: V75I
Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
HIV mutation literature information.
PMID: 
2021
The Pan African medical journal
Browser Board
Co-occurred Entities
Filtrator
ViMRT